Licensed real-world data arrives retrospective, de-identified and several hands from the clinician who produced it. Commission a Circle instead: the Observational Protocol defines the episode your product sits in, and every treating clinician and patient records it, from baseline to long-term outcome.
The median pivotal trial for drugs approved in 2015–2016 cost an estimated $19 million, and two-thirds of new drug indications approved in 2005–2012 had no pivotal trial lasting six months. A Circle is commissioned once against your protocol and keeps producing submission, post-market and comparative evidence from the same Cases.
Comparative and post-market claims drawn from de-identified, multi-hand data are hard to defend once challenged, because the chain from patient to record is already broken. A Circles Dataset preserves the attesting clinician and time on every record, so a claim can be defended down to its clinical source.
FDA’s December 2025 guidance asks device sponsors to show real-world data are relevant and reliable, whatever the source. For drugs, 85% of recent approvals reviewed included real-world evidence. A Circles Dataset meets those tests from the first Case, not reconstructed from claims.
Each runs on the same four pillars: the Observational Protocol, the Circle, the closed system and the technical stack. The regulatory and statistical detail sits in the linked white papers.
State the hypothesis first, then record the whole episode that answers it, including co-interventions and patients trials exclude.
A retrospective extract forces the analysis to accept whatever was recorded for billing. A Circle inverts that: the Observational Protocol defines the question and the attribute set, sites enroll cases against it, and clinicians attest to each measure at the visit. The dataset arrives with the noise removed by construction rather than by adjustment.
Evidence with provenance intact from clinician to reviewer, for label expansion, investigational device exemptions and rare disease confirmatory evidence, where FDA now accepts natural history and expanded access data.
Every value carries its attesting clinician and time, so a reviewer can test an individual record instead of accepting an aggregate. Zero-knowledge verification is in pilot.
FDA Section 522 studies, EU post-market clinical follow-up before the 2027–2028 deadlines, and long-term safety signals, inside routine care.
Post-market commitments usually run as a separate study with its own coordinators, which is why completeness decays after year one. Because capture happens through inCytes™ during the ordinary visit, longitudinal follow-up continues as long as the patient is seen, and the same capture event can serve internal safety review and society registry reporting.
Show how your product performs against alternatives in the same population, for value committees, TCET and CED, and EU joint clinical assessment.
Value-analysis committees and payers now ask for comparison in routine practice, not trial conditions. A national Circle holds the same attribute set across sites and manufacturers, so a sponsor can read its product against the cohort on defined endpoints — and hold a defensible position when a committee questions the source.
Commission a Private Circle for your product, or license non-exclusive datasets, including ones not yet captured.
Sponsors fund Circles directly with participating sites rather than buying assembled extracts from a broker. Circle Members typically retain 85% of a Circles Dataset's monetization and RegenMed retains 15%, with patient consent rights recorded on Circle Health Coin. Licensing terms are transacted on the exchange, so the parties in the transaction are the parties that produced the evidence.
Sources: FDA CDRH Annual Report 2025; Purpura et al., Clinical Pharmacology & Therapeutics (2022); Mercuri and Wickline, JOEI (2026); Moore et al., JAMA Internal Medicine (2018); Downing et al., JAMA (2014).
FDA decides case by case whether data are relevant and reliable for the decision at hand. Circles data is designed to meet those tests: prespecified, attributable, complete and traceable. Agreeing the protocol with FDA in a pre-submission meeting is the usual route.
A Circle is neither a chart-abstraction registry nor an interventional trial. It records a protocol-defined episode inside routine care, so it can extend a trial’s follow-up for years, run alongside a trial program, or replace a registry that depends on abstraction.
Yes. Expert clinicians design the protocol with you, and Circle Members enroll every eligible patient. A Circle limited to your product is a Private Circle; your counsel confirms its Anti-Kickback and Stark compliance.
You receive a licensed, de-identified Circles Dataset or verified conclusions. The Cases stay with the Circle Members who created them, and licenses through the Exchange are non-exclusive.